Outstanding Growth of Clinical Immunoanalyzer Market is estimated to reach $4.95 Billion by 2025 | Roche, Abbott, Siemens, Beckman Coulter, Ortho-Clinical Diagnostics, Bio-Rad, BioMerieux

Global Clinical Immunoanalyzer Market Synopsis:

The report covers a forecast and an analysis of the Clinical Immunoanalyzer Market on a global and regional level. The study provides historical data for 2015, 2016, 2017 and 2018 along with a forecast from 2020 to 2025 based on revenue (USD Million) and volume (Kilotons). The study includes drivers and restraints of the Clinical Immunoanalyzer Market along with the impact they have on the demand over the forecast period.

The Global Clinical Immunoanalyzer Market has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Clinical Immunoanalyzer market size to maintain the average annual growth rate of 0.05275340306 from US$ 2900.0 Million in 2015 to US$ 3750.0 Million in 2019, market analysts believe that in the next few years, Clinical Immunoanalyzer market size will be further expanded, we expect that by 2025, The market size of the Clinical Immunoanalyzer will reach US$ 4950.0 Million.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/286784 .

According to the market research study, Immunoassay is test to measure the concentration or presence of a molecule via an antibody or an antigen. The molecule detected through this test is termed as an ‘analyte’ and in some cases also as protein. Clinical Immunoanalyzer is a medical diagnostic device that identifies and quantifies specific analytes in the blood or samples of body fluids by using immunoassay processes, such as, immunoprecipitation, particle immunoassays, immunonephelometry, radioimmunoassay, enzyme immunoassay, fluorescent immunoassay, and chemiluminescent immunoassays. Clinical Immunoanalyzer is used in the medical sector for the detection of bacteria & viral toxins, drug monitoring, allergy testing, and cancer markers.

Some of the significant key factors driving the growth of the Global Clinical Immunoanalyzer Market are rapid growth in the prevalence of chronic & infectious diseases around the globe, increasing demand for diagnostics, and increasing investments in Research & Development to develop new tests for the diagnosis of the diseases.

On the basis of Regional analysis, North America and Europe holds major share in global Clinical Immunoanalyzer market. Moreover, Asia-Pacific is expected to record higher growth rate in Clinical Immunoanalyzer Market during the forecast year.

Global Key Players:

1 Roche Diagnostics

2 Abbott

3 Siemens

4 Beckman Coulter

5 Ortho-Clinical Diagnostics

6 Bio-Rad

7 BioMerieux

8 DiaSorin

9 Werfen Life

10 Thermo Fisher Scientific

11 Tosoh Corporation

12 Randox Laboratories

13 Snibe

14 Transasia and More………………

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Clinical Immunoanalyzer Market Report 2021” @ https://www.businessindustryreports.com/buy-now/286784/single .

Product Type Segmentation

1 CLIA

2 ELISA

3 RIA

4 FIA

Industry Segmentation

1 Hospital

2 Clinic

Latest Medical Industry News:

Roche (March 30, 2021) - Roche’s Evrysdi approved by European Commission as first and only at home treatment for spinal muscular atrophy - Roche today announced that the European Commission (EC) has approved Evrysdi (risdiplam) for the treatment of 5q spinal muscular atrophy (SMA) in patients two months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. SMA is a leading genetic cause of death in infants and 5q SMA is the most common form of the disease. The condition causes muscle weakness and progressive loss of movement and significant unmet need remains, particularly in adults living with this condition.

“Today’s approval of Evrysdi, the first and only SMA treatment with proven efficacy that can be taken at home, potentially transforms treatment options for a broad range of people with SMA living in the EU,” said Levi Garraway, M.D., Ph. D., Roche’s Chief Medical Officer and Head of Global Product Development. “By avoiding the need for in-hospital administration, Evrysdi can reduce the treatment burden on those living with SMA, their caregivers and healthcare systems. We thank the SMA community for their partnership, the trust they have placed in us and their unyielding commitment to achieve this significant milestone.”

The approval is based on data from two clinical studies, designed to represent a broad spectrum of people living with SMA: FIREFISH in symptomatic Type 1 infants aged 2 to 7 months and SUNFISH in symptomatic Type 2 and 3 children and adults aged 2 to 25 years. SUNFISH is the first and only placebo-controlled trial to include adults with Types 2 and 3 SMA. Evrysdi demonstrated a favourable efficacy and safety profile, with the safety profile established across both trials.

"We welcome today’s approval of Evrysdi for people with SMA in Europe, and are proud of the role we have played in its development and of our partnership with Roche,” said Dr Nicole Gusset, President of SMA Europe. “A recent survey conducted by SMA Europe showed that a large proportion of people with SMA in the EU were not receiving an approved treatment which leaves them feeling helpless and frustrated. It is vital that we work together with health authorities, regulators and industry to ensure we can get this medicine to the patients who need it as soon as possible.’’

Roche is working closely with reimbursement and assessment bodies in European countries to enable broad and rapid access to patients in need. Evrysdi will be accessible to patients in Germany in the coming days and in France from early April through the cohort Temporary Authorization for Use. Reimbursement dossiers have been submitted in many countries in anticipation of today’s decision by the European Commission to minimise any delay in patient access.

The decision from the European Commission follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) in February 2021. The review was completed under the accelerated assessment pathway for medicines, which is offered to medicines deemed to be of major interest for public health and therapeutic innovation. This approval is applicable to all 27 European Union member states, as well as Iceland, Norway, and Liechtenstein. Evrysdi was granted PRIME designation by the European Medicines Agency (EMA) in 2018 and Orphan Drug Designation in 2019. Maintenance of Orphan Drug Designation was recently confirmed by the Committee for Orphan Medicinal Products based on the assumption of Evrysdi’s significant benefit over existing treatments. Evrysdi has been approved in 38 countries and submitted in further 33 countries.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/286784 .

Major Points in Table of Contents:

Global Clinical Immunoanalyzer Market Report 2021

1 Clinical Immunoanalyzer Product Definition

2 Global Clinical Immunoanalyzer Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Clinical Immunoanalyzer Shipments

2.2 Global Manufacturer Clinical Immunoanalyzer Business Revenue

2.3 Global Clinical Immunoanalyzer Market Overview

2.4 COVID-19 Impact on Clinical Immunoanalyzer Industry

3 Manufacturer Clinical Immunoanalyzer Business Introduction

3.1 Roche Diagnostics Clinical Immunoanalyzer Business Introduction

3.2 Abbott Clinical Immunoanalyzer Business Introduction

3.3 Siemens Clinical Immunoanalyzer Business Introduction

3.4 Beckman Coulter Clinical Immunoanalyzer Business Introduction

3.5 Ortho-Clinical Diagnostics Clinical Immunoanalyzer Business Introduction

3.6 Bio-Rad Clinical Immunoanalyzer Business Introduction

About us

BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that hold the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.